Jasper Therapeutics tumbles after unveiling equity offering plans

** Shares of Jasper Therapeutics JSPR.O down 13% in extended trading to $2.25 as co seeks equity raise

** Redwood City, California-based JSPR announces proposed offering of stock and warrants; deal size not disclosed

** Co says intends to use net proceeds to advance preclinical/clinical development programs of briquilimab in mast-cell driven diseases, and for general purposes, including capex, among other uses

** TD Cowen is sole bookrunner for offering

** With ~16.3 mln shares outstanding, co has about $42 mln market cap

** JSPR shares on Thurs ended up 11.2% at $2.59, trimming YTD loss to ~88%

** On Jul 7, shares plunged 55% to close at $3.04 after co halted its asthma trial for briquilimab due to a drug product lot issue that affected potency

** Two days later, JSPR announced a 50% workforce reduction and said it is halting other clinical programs to focus on briquilimab

** 6 of 10 analysts covering JSPR rate the stock "strong buy" or "buy", rest rate "hold"; median PT of $20 down from $48 on Jun 18, LSEG data reflects